Cervical cancer is the fourth most common cancer in women, with a five-year survival rate of 66%. Cases are largely caused by human papillomavirus (HPV) infection. Globally, cervical screenings help prevent the development of cervical cancer by assessing cervical cells for abnormalities and testing for HPV. In November 2021, the Lancet published a study showing how the national HPV vaccination program in England was highly successful at decreasing the risk of developing cervical cancer. The vaccination program focused on vaccinating girls between the ages of 12–13, and results showed a substantial reduction in cervical cancer and incidence of cervical intraepithelial neoplasia III (CIN3) in young women. Global immunisation of the HPV vaccine has been low, with a recent PubMed study showing that the immunisation coverage is approximately 12.2%.
According to GlobalData’s Clinical Trials Database, the number of cervical cancer trials peaked at 190 trials in 2021 (Figure 1). When assessing these trials, many focused on the efficacy of vaccination programs within specific countries, while others focused on treatment therapies. Globally, the US had the greatest portion of cervical cancer trials with 32.3%, followed by China with 24.7%.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
